Cargando…
The efficacy and safety of Dendropanax morbifera leaf extract on the metabolic syndrome: a 12-week, placebo controlled, double blind, and randomized controlled trial
BACKGROUND/OBJECTIVES: The extract from Dendropanax morbifera exhibited diverse therapeutic potentials. We aimed to evaluate the efficacy and safety of D. morbifera leaf extract for improving metabolic parameters in human. SUBJECTS/METHODS: A 12-week, double blind, placebo-controlled and randomized...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Nutrition Society and the Korean Society of Community Nutrition
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784258/ https://www.ncbi.nlm.nih.gov/pubmed/35116128 http://dx.doi.org/10.4162/nrp.2022.16.1.60 |
_version_ | 1784638695990624256 |
---|---|
author | Jun, Ji Eun Hwang, You-Cheol Ahn, Kyu Jeung Chung, Ho Yeon Choung, Se Young Jeong, In-Kyung |
author_facet | Jun, Ji Eun Hwang, You-Cheol Ahn, Kyu Jeung Chung, Ho Yeon Choung, Se Young Jeong, In-Kyung |
author_sort | Jun, Ji Eun |
collection | PubMed |
description | BACKGROUND/OBJECTIVES: The extract from Dendropanax morbifera exhibited diverse therapeutic potentials. We aimed to evaluate the efficacy and safety of D. morbifera leaf extract for improving metabolic parameters in human. SUBJECTS/METHODS: A 12-week, double blind, placebo-controlled and randomized trial included a total of 74 adults, and they were assigned to the placebo group (n = 38) or 700 mg/day of D. morbifera group (n = 36). The efficacy endpoints were changes in glycemic, lipid, obesity, and blood pressure (BP) parameters, in addition to the prevalence of metabolic syndrome (MetS) and the numbers of MetS components. Safety was assessed by monitoring adverse events (AEs). RESULTS: After 12 weeks of treatment, the hemoglobin A1c (HbA1c) level significantly decreased in the D. morbifera group compared to that of the placebo group (difference: −0.13 ± 0.20% vs. 0.00 ± 0.28%, P = 0.031; % of change: −2.27 ± 3.63% vs. 0.10 ± 5.10%, P = 0.025). The homeostatic model assessment for insulin resistance level also decreased significantly from its baseline in the D. morbifera group. The systolic BP of D. morbifera group decreased significantly than that of placebo group (difference: −3.9 ± 9.8 mmHg vs. 3.3 ± 11.7 mmHg, P = 0.005; % of change: −2.8 ± 7.7% vs. 3.3 ± 10.2%, P = 0.005). However, the lipid parameters and body composition including body weight did not differ between the groups. The prevalence of MetS (36.8% vs. 13.9%, P = 0.022) and the incidence of MetS (10.5% vs. 13.9%, P = 0.027) at 12 weeks was significantly lower in the D. morbifera group than it was in the placebo group. No serious AEs occurred in either group. CONCLUSIONS: Supplementation with D. morbifera extracts over a 12-week period improved metabolic parameters such as HbA1c and BP and reduced the prevalence of MetS. TRIAL REGISTRATION: Clinical Research Information Service Identifier: KCT0004672 |
format | Online Article Text |
id | pubmed-8784258 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Korean Nutrition Society and the Korean Society of Community Nutrition |
record_format | MEDLINE/PubMed |
spelling | pubmed-87842582022-02-02 The efficacy and safety of Dendropanax morbifera leaf extract on the metabolic syndrome: a 12-week, placebo controlled, double blind, and randomized controlled trial Jun, Ji Eun Hwang, You-Cheol Ahn, Kyu Jeung Chung, Ho Yeon Choung, Se Young Jeong, In-Kyung Nutr Res Pract Original Research BACKGROUND/OBJECTIVES: The extract from Dendropanax morbifera exhibited diverse therapeutic potentials. We aimed to evaluate the efficacy and safety of D. morbifera leaf extract for improving metabolic parameters in human. SUBJECTS/METHODS: A 12-week, double blind, placebo-controlled and randomized trial included a total of 74 adults, and they were assigned to the placebo group (n = 38) or 700 mg/day of D. morbifera group (n = 36). The efficacy endpoints were changes in glycemic, lipid, obesity, and blood pressure (BP) parameters, in addition to the prevalence of metabolic syndrome (MetS) and the numbers of MetS components. Safety was assessed by monitoring adverse events (AEs). RESULTS: After 12 weeks of treatment, the hemoglobin A1c (HbA1c) level significantly decreased in the D. morbifera group compared to that of the placebo group (difference: −0.13 ± 0.20% vs. 0.00 ± 0.28%, P = 0.031; % of change: −2.27 ± 3.63% vs. 0.10 ± 5.10%, P = 0.025). The homeostatic model assessment for insulin resistance level also decreased significantly from its baseline in the D. morbifera group. The systolic BP of D. morbifera group decreased significantly than that of placebo group (difference: −3.9 ± 9.8 mmHg vs. 3.3 ± 11.7 mmHg, P = 0.005; % of change: −2.8 ± 7.7% vs. 3.3 ± 10.2%, P = 0.005). However, the lipid parameters and body composition including body weight did not differ between the groups. The prevalence of MetS (36.8% vs. 13.9%, P = 0.022) and the incidence of MetS (10.5% vs. 13.9%, P = 0.027) at 12 weeks was significantly lower in the D. morbifera group than it was in the placebo group. No serious AEs occurred in either group. CONCLUSIONS: Supplementation with D. morbifera extracts over a 12-week period improved metabolic parameters such as HbA1c and BP and reduced the prevalence of MetS. TRIAL REGISTRATION: Clinical Research Information Service Identifier: KCT0004672 The Korean Nutrition Society and the Korean Society of Community Nutrition 2022-02 2021-06-29 /pmc/articles/PMC8784258/ /pubmed/35116128 http://dx.doi.org/10.4162/nrp.2022.16.1.60 Text en ©2022 The Korean Nutrition Society and the Korean Society of Community Nutrition https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Jun, Ji Eun Hwang, You-Cheol Ahn, Kyu Jeung Chung, Ho Yeon Choung, Se Young Jeong, In-Kyung The efficacy and safety of Dendropanax morbifera leaf extract on the metabolic syndrome: a 12-week, placebo controlled, double blind, and randomized controlled trial |
title | The efficacy and safety of Dendropanax morbifera leaf extract on the metabolic syndrome: a 12-week, placebo controlled, double blind, and randomized controlled trial |
title_full | The efficacy and safety of Dendropanax morbifera leaf extract on the metabolic syndrome: a 12-week, placebo controlled, double blind, and randomized controlled trial |
title_fullStr | The efficacy and safety of Dendropanax morbifera leaf extract on the metabolic syndrome: a 12-week, placebo controlled, double blind, and randomized controlled trial |
title_full_unstemmed | The efficacy and safety of Dendropanax morbifera leaf extract on the metabolic syndrome: a 12-week, placebo controlled, double blind, and randomized controlled trial |
title_short | The efficacy and safety of Dendropanax morbifera leaf extract on the metabolic syndrome: a 12-week, placebo controlled, double blind, and randomized controlled trial |
title_sort | efficacy and safety of dendropanax morbifera leaf extract on the metabolic syndrome: a 12-week, placebo controlled, double blind, and randomized controlled trial |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784258/ https://www.ncbi.nlm.nih.gov/pubmed/35116128 http://dx.doi.org/10.4162/nrp.2022.16.1.60 |
work_keys_str_mv | AT junjieun theefficacyandsafetyofdendropanaxmorbiferaleafextractonthemetabolicsyndromea12weekplacebocontrolleddoubleblindandrandomizedcontrolledtrial AT hwangyoucheol theefficacyandsafetyofdendropanaxmorbiferaleafextractonthemetabolicsyndromea12weekplacebocontrolleddoubleblindandrandomizedcontrolledtrial AT ahnkyujeung theefficacyandsafetyofdendropanaxmorbiferaleafextractonthemetabolicsyndromea12weekplacebocontrolleddoubleblindandrandomizedcontrolledtrial AT chunghoyeon theefficacyandsafetyofdendropanaxmorbiferaleafextractonthemetabolicsyndromea12weekplacebocontrolleddoubleblindandrandomizedcontrolledtrial AT choungseyoung theefficacyandsafetyofdendropanaxmorbiferaleafextractonthemetabolicsyndromea12weekplacebocontrolleddoubleblindandrandomizedcontrolledtrial AT jeonginkyung theefficacyandsafetyofdendropanaxmorbiferaleafextractonthemetabolicsyndromea12weekplacebocontrolleddoubleblindandrandomizedcontrolledtrial AT junjieun efficacyandsafetyofdendropanaxmorbiferaleafextractonthemetabolicsyndromea12weekplacebocontrolleddoubleblindandrandomizedcontrolledtrial AT hwangyoucheol efficacyandsafetyofdendropanaxmorbiferaleafextractonthemetabolicsyndromea12weekplacebocontrolleddoubleblindandrandomizedcontrolledtrial AT ahnkyujeung efficacyandsafetyofdendropanaxmorbiferaleafextractonthemetabolicsyndromea12weekplacebocontrolleddoubleblindandrandomizedcontrolledtrial AT chunghoyeon efficacyandsafetyofdendropanaxmorbiferaleafextractonthemetabolicsyndromea12weekplacebocontrolleddoubleblindandrandomizedcontrolledtrial AT choungseyoung efficacyandsafetyofdendropanaxmorbiferaleafextractonthemetabolicsyndromea12weekplacebocontrolleddoubleblindandrandomizedcontrolledtrial AT jeonginkyung efficacyandsafetyofdendropanaxmorbiferaleafextractonthemetabolicsyndromea12weekplacebocontrolleddoubleblindandrandomizedcontrolledtrial |